BIG news.(BSNS WIRE) STGI Signs $20 Million Funding Agreement
STGI Signs $20 Million Funding Agreement
Business Editors/Health & Medical Writers
LAS VEGAS--(BW HealthWire)--July 26, 2000--(OTCBB:STGI-news)
Steroidogenesis Inhibitors International, Inc. is pleased to announce
the signing of an agreement with Investment Bankers Josephberg Grosz &
Co., Inc., a New York based international investment banking firm.
They specialize in structuring financial transactions for U.S. and
foreign-based public and private companies along with providing
private equity and debt capital from institutional investors for
working capital, mergers, acquisitions, refinancing and management
buyouts.
Some of the Companies to which Josephberg Grosz & Co., Inc. has
provided Investment and Merchant Banking Services have been, Applied
DNA Systems, BioDental Technologies Corp, GIA Research Company,
NutraMax Products Inc., Oxygen Enrichment Company, Ltd. and
Allscripts.
Richard Josephberg, who had been a securities analyst at Goldman
Sachs & Co. and also a member of the New York Stock Exchange stated "I
am excited about the opportunity of working with STGI and believe that
with the appropriate financing, and this management team, combined
(BSNS WIRE) STGI Signs $20 Million Funding Agreement
STGI Signs $20 Million Funding Agreement
Business Editors/Health & Medical Writers
LAS VEGAS--(BW HealthWire)--July 26, 2000--(OTCBB:STGI-news)
Steroidogenesis Inhibitors International, Inc. is pleased to announce
the signing of an agreement with Investment Bankers Josephberg Grosz &
Co., Inc., a New York based international investment banking firm.
They specialize in structuring financial transactions for U.S. and
foreign-based public and private companies along with providing
private equity and debt capital from institutional investors for
working capital, mergers, acquisitions, refinancing and management
buyouts.
Some of the Companies to which Josephberg Grosz & Co., Inc. has
provided Investment and Merchant Banking Services have been, Applied
DNA Systems, BioDental Technologies Corp, GIA Research Company,
NutraMax Products Inc., Oxygen Enrichment Company, Ltd. and
Allscripts.
Richard Josephberg, who had been a securities analyst at Goldman
Sachs & Co. and also a member of the New York Stock Exchange stated "I
am excited about the opportunity of working with STGI and believe that
with the appropriate financing, and this management team, combined
with STGI's core technology and growth potential, it will become a
major force in the pharmaceutical industry."
Josephberg's immediate focus will be in providing the Company with
equity for working capital needs in the $5,000,000 range and
acquisition capital in the $15,000,000 range.
Dr. Janet Greeson, President of STGI stated, "We are excited about
the signing of this financial endeavor. This financing is a vote of
confidence in the present management team that was impossible to get
under the previous leadership. Management is finally a team that is
driven to enhance shareholder value." Dr. Greeson continued "This is
just the beginning of how we are going to demonstrate to our
shareholders that we can turn STGI into a pharmaceutical company that
can't be ignored."
Bert Wollen, CEO elaborated, "We are being positioned to become a
significant company and we think "the street" is embracing our new
direction as demonstrated by this agreement. Richard Josephberg is
extremely professional and has the caliber of the people that we want
to deal with in the future."
STGI is a pioneer in anti-cortisol research. Over the past ten
years, Cortisol (the stress hormone) has become internationally
recognized as a major immune-suppressive hormone, which influences the
body's system to either "fight or flight". University and clinical
studies on the Company's ANTICORT(TM) drug are currently under way
both domestically and in Europe.
STGI is actively seeking to enhance its technology portfolio in
the anti-cortisol field and its delivery systems
This release contains statements about the future that could
differ from actual results. The statements are subject to risk and
uncertainties, including, but not limited to, the impact of
competition, fluctuations in stock price and liquidity, fluctuating
operating results and other risks.
STGI is a pharmaceutical company with its core technology being
ANTICORT(TM), which is currently in FDA Phase 1B/2A clinical trials as
an anticortisol drug for the treatment of HIV positives.
This Release Contains Statements About the Future That Could
Differ From Actual Results. the Statements are Subject to Risk and
Uncertainties, Including, But Not Limited To, the Impact of
Competition, Fluctuations in Stock Price and Liquidity, Fluctuating
Operating Results and Other Risks.
--30--jd/ph*
CONTACT: Steroidogenesis Inhibitors, Intl
Dr. Janet Greeson, 702/222-1988
or
Columbia Financial Group
Brokers and Analysts
888/301-6271
or
Performance Strategies, Inc.
Richard L. Brown and
Chuck Jordan, 303/948-3601
KEYWORD: NEVADA
INDUSTRY KEYWORD: BANKING MEDICAL MEDICAL DEVICES MARKETING
AGREEMENTS
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
URL: businesswire.com |
